Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT

Annals of Nuclear Medicine

Volumn 29, Issue 10, 2015, Pages 877-882

  Rowe, Steven P ^a   Gorin, Michael A ^a   Hammers, Hans J ^b   Som Javadi, M ^a   Hawasli, Hazem ^a   Szabo, Zsolt ^a   Cho, Steve Y ^c   Pomper, Martin G ^a,b   Allaf, Mohamad E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

DCFPyL; Positron emission tomography (PET); Prostate specific membrane antigen (PSMA); Renal cell carcinoma (RCC)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; 2-(3-(1-CARBOXY-5-((6-FLUOROPYRIDINE-3-CARBONYL)AMINO)PENTYL)UREIDO)PENTANEDIOIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LYSINE; MEMBRANE ANTIGEN; UREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPH NODE; MALE; METASTASIS; MIDDLE AGED; MOLECULAR IMAGING; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; KIDNEY NEOPLASMS; METABOLISM; MULTIMODAL IMAGING; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTIGENS, SURFACE; CARCINOMA, RENAL CELL; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; KIDNEY NEOPLASMS; LYSINE; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; UREA;

EID: 84949100113     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-015-1017-z     Document Type: Article

References (12)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
2. Brufau BP, Cerqueda CS, Villalba LB, Izquierdo RS, González BM, Molina CN. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted therapy by using multidetector CT. Radiographics. 2013;33:1691–716.
3. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.
4. 18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012;12:464–74.
5. Calderella C, Muoio B, Isgrò MA, Porfiri E, Treglia G, Giovanella L. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiol Oncol. 2014;48:219–27.
6. Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–81.
7. Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–90.
8. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2.
9. 18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53.
10. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74.
11. Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2015;67:85–97.
12. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large multicenter study. J Clin Oncol. 2009;27:5794–9.